1 / 30

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE. ZULEYHA OZEN. OVERVIEW. Introduction Information about Chronic Obstructive Pulmonary Disease (COPD ) Inflammatory Responses Paper 1 Paper 2 What is still unknown? Future Studies/Specific Aim. Disease Overview .

hye
Télécharger la présentation

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE ZULEYHA OZEN

  2. OVERVIEW • Introduction • Information about Chronic Obstructive Pulmonary Disease (COPD) • Inflammatory Responses • Paper 1 • Paper 2 • What is still unknown? • Future Studies/Specific Aim

  3. Disease Overview • Pathophysiology of COPD(Chronic Bronchitis and Emphysema) -Chronic Bronchitis: Loss of muco-ciliary clearance • Loss of cilia function -Emphysema: Destruction of elastin fibers • Proteases, matrix metalloproteinase 9 (MMP9) cause elastin degradation Shortness of Breath Cough/Sputum-(Progressive dyspnea) http://www.wgabinecie.pl/artykul/65-pochp-przewlekla-obturacyjna-choroba-pluc/

  4. Current existing medicines Bronchodilators Combination of Bronchodilators and cortisteroids Vaccines Pulmonary Rehabilitation Oxygen Therapy Change in Lifestyle

  5. http://www.ncbi.nlm.nih.gov/books/NBK26827/figure/A4531/?report=objectonlyhttp://www.ncbi.nlm.nih.gov/books/NBK26827/figure/A4531/?report=objectonly https://www.caymanchem.com/app/template/Article.vm/article/2177

  6. Inflammatory and immune cells involved in chronic obstructive pulmonary disease (COPD) Macrophages and epithelial cells: -chemotactic factors -attract inflammatory cells http://www.nature.com/nri/journal/v8/n3/fig_tab/nri2254_F2.html

  7.  TH17 cells and airway inflammation http://www.nature.com/nri/journal/v8/n3/fig_tab/nri2254_F5.html

  8. Smoke Exposure (n=20/group)Whole body exposed to cigarette smoke (CS) 20 mice exposed to CS of 5 cigarettes 20 mice exposed to CS of 5 cigarettes 20 mice exposed to CS of 5 cigarettes 20 mice exposed to CS of 5 cigarettes 30 min smoke free interval 30 min smoke-free interval 30 min smoke-free interval The CS exposure animals were divided into two subgroups: Control group: exposed to air Sub-acute exposure: Initiated CS at 26-28 weeks old Chronic exposure: initiated CS at 6-8 weeks old Mice of each group 30-32 weeks old when the CS & Air exposure ended

  9. Figure 1. Assessing effect of CS exposure on lung inflammation • Total number of alveolar inflammatory cells increased in chronic CS exposure • Sub-acute exposure significantly lower than chronic CS

  10. Figure 2A. Prevalence of Th17 cells in lung tissue Prevalence of Th17 cells: -ratio of CD4+ IL-17A+ cells to the total amount of CD4+ T lymphocytes -Th17 prevalence markedly higher in mice with chronic CS and Sub-acute CS

  11. Figure 2B. Peripheral blood mononuclear cells -similarly the prevalence of Th17 cells increased in CS exposure Figure 2C. Collective analysis of flow cytometry

  12. Figure 3A. Prevalence of T regulatory cells (ratio of CD4+CD25+Foxp3+ cells to the total amount of CD4+ T lymphocytes) in lung tissue Prevalence of T regulatory cells: -markedly higher in sub-acute exposure -drops in chronic CS exposure

  13. Figure 3B. Peripheral blood mononuclear cells-similarly the prevalence of T regulatory cells decreased in chronic CS exposure Figure 3C. Collective analysis of flow cytometry

  14. Figure 4. Assessing the ratio of Th17 and Treg in lung tissue and peripheral blood -In lung tissues, the ratio of Th/Treg is decreased with sub-acute CS exposure -Increases in chronic CS exposure Ratio of Th17/Tregin peripheral blood: -significantly increased in chronic CS exposure

  15. Figure 5. The expression of Foxp3 and ROR gamma t mRNA -Looking at specific transcription factors of both T-subsets by real time-PCR -Th17 specific transcription factor ROR gamma t mRNA expression: significantly increased in CS exposed -T regulatory specific transcription factor Foxp3 mRNA expression: significantly decreased in CS exposed

  16. Table 1: levels of IL-17A, IL-6, IL-23 and TGF-beta in serum significantly higher in chronic CS exposure -IL-10 sig. lower in chronic CS

  17. Conclusions from paper 1 • There is an obvious imbalance between Th/Treg cells in CS exposed mice • Prevalence of Th17 and Th17 specific transcription factor, ROR gamma t mRNA: increased • Treg cell prevalence and Treg specific transcription factor, Foxp3 mRNA: decreased • Thus, leading to an imbalance in the ratio of Th/Treg cell profiles • The existing cytokine profile can be further evaluated for specific therapeutic approach

  18. Figure 1. Assessing histology of lung tissues Fig.1 Histology of Lung Tissues • Mean alveoli were expanded and broken • COPD lung- more inflammatory cells

  19. Figure 2. Expression of transcription factors ROR gamma t and Foxp3 • Fig.2a. Foxp3 relative mRNA expression level significantly lower in COPD patients • Fig.2b. RORyt relative mRNA expression level significantly higher in COPD patients • Fig.2c. Ratio of Treg/Thelper cells in the level of mRNA lower in COPD patients

  20. Figure 3. Assessing expression of Foxp3 and ROR gamma t protein levels -Increased protein expression of ROR gamma t in COPD patients -Viceversa, decreased protein expression of Foxp3 compared with smokers and nonsmokers

  21. Figure 4. Immunohistochemistry staining of different proteins All p-values were less than 0.001 -IL-17+, CCR6+ and IL-23R cells increased -Foxp3 cells in alveolar walls decreased

  22. Figure 5. The number of Foxp3+, IL-17+, CCR6+ and IL-23R+ cells in alveolar walls -Foxp3+ and Foxp3+ / IL-17+ cells decreased in cell number in chronic CS exposure -IL-17+, CCR6+ and IL-23R+ cells increased in cell number in chronic CS exposure • -Foxp3+ & Foxp3+/IL-17+ cells decreased in alveolar walls of COPD

  23. A: ROR gamma t & Foxp3 mRNA expression: negatively correlated B: Ratio of Foxp3/ROR gamma t mRNA expression negatively correlated with mean alveoli area C: Positive correlation with the ratio of Foxp3/ROR gamma t and FEV1%pred

  24. D: ROR gamma t & Foxp3 protein: negatively correlated E: Ratio of Foxp3/ROR gamma t in level of protein and mean alveoli area F: Positive correlation with the ratio of Foxp3/ROR gamma t in level of protein and FEV1%pred

  25. G: Numbers of Foxp3+/IL-17+ cells: negatively correlated H: Ratio of Foxp3/IL-17+ cells: negatively correlated to the mean alveoli area I: Positive correlation with the ratio of Foxp3+/IL-17+ cells and FEV1%pred

  26. Conclusions from paper 2 • Decreased ratio of Foxp3/ROR gamma t in patients with COPD and normal smokers • persistent with the aggravation of the disease • Decreased ratio of Foxp3/ROR gamma t important in pathogenesis of COPD • Immune dysregulation, and participation in lung inflammation: leading to destruction in the lung • Pro-inflammatory cytokines and chemokine receptors are also evident in development of the disease • Their association with the transcription factors ROR gamma t and Foxp3 can be further researched for potential therapeutics

  27. What is still unknown ? The regulatory cytokine involvement: TGF-beta levels in the progression of the disease is still unknown Study by Zhou et al. TGF-beta induced Foxp3 leads to inhibition of Th17 cell differentiation In a dose dependent matter, TGF-beta might be a factor seen in the imbalance between Th/T regulatory cells Specific Aim • In the research proposal, my area of focus will be to further analyze the negatively correlated relationship between the T-regulatory and T helper cells with regards to changes in the expression of the specific transcription factors and cytokine TGF-beta • Implement TGF-beta induced Foxp3 and use of cytokine IL-6 antagonist for therapeutic approach

  28. THANK YOU! QUESTIONS?

More Related